SEC Form 4 · accession 0001640455-18-000022
Jounce Therapeutics, Inc. · JNCE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kimberlee C Drapkin
Officer — CFO and Treasurer
Period of report
Mar 5, 2018
Accepted (ET)
Mar 7, 2018 · 6:57 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001640455
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Mar 5, 2018 | S | 4,000 | $21.21 | D | 2,775 | D | |
| Common StockF3 | Mar 5, 2018 | S | 1,267 | $22.07 | D | 1,508 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. The Reporting Person exercised no discretion with respect to the trades.
- F2Represents the weighted average share price of an aggregate total of 4,000 shares sold in the price range of $20.89 to $21.86 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3Represents the weighted average share price of an aggregate total of 1,267 shares sold in the price range of $21.89 to $22.20 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.